Impact of Targeted Therapy on Cancer-Related Cognitive Impairment

Part of paid clinical trials in Rochester, New York.

Sponsor
University of Rochester NCORP Research Base
Study ID
NCT07638007
Status
Recruiting
Apply to this trial

Conditions

  • Chronic Lymphocytic Leukemia (CLL)
  • Chronic Myeloid Leukemia, BCR-ABL1 Positive
  • Disease/Condition Name Cancer-related Cognitive Dysfunction

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Study Details

This study examines whether there are differences in brain health or well-being in patients receiving TKI therapy for leukemia compared to individuals who do not receive TKI therapy.

Key Dates

Start date
Nov 21, 2025
Status verified
Jun 2026
Primary completion
Feb 28, 2029
Completion
Feb 28, 2029

Study Design

Enrollment
400 participants (estimated)

Arms

  • Arm: Observational group I
    TKI recipients complete surveys, undergo cognitive assessments, undergo saliva sample collection, and have their medical records reviewed on study.
  • Arm: Observational group II
    Cancer-free individuals complete surveys, undergo cognitive assessments, undergo saliva sample collection, and have their medical records reviewed on study.

Primary Outcome Measure

Subjective cognitive performance [ Time Frame: 12 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Rochester NCORP Research BaseRochesterNew York14642
Ashley Mack
[email protected]
585 - 275 - 1361
Karen Mustian, PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Rochester, NY

By research site
University of Rochester NCORP Research Base· Rochester, NY

Related Studies